A Systematic Review Supporting the Endocrine Society Guidelines: Management of Diabetes and High Risk of Hypoglycemia
The Journal of Clinical Endocrinology & Metabolism · 15.02.2023 · 108 (3) · 592-603
DOI: 10.1210/clinem/dgac601 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 07.12.2022. Verfasst von Victor D Torres Roldan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic Evidence-Based Practice Center, Rochester, MN 55902, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Hypoglycemia. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 184 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Context
Interventions targeting hypoglycemia in people with diabetes are important for improving quality of life and reducing morbidity and mortality.
Objective
To support development of the Endocrine Society Clinical Practice Guideline for management of individuals with diabetes at high risk for hypoglycemia.
Methods
We searched several databases for studies addressing 10 questions provided by a guideline panel from the Endocrine Society. Meta-analysis was conducted when feasible. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess certainty of evidence.
Results
We included 149 studies reporting on 43 344 patients. Continuous glucose monitoring (CGM) reduced episodes of severe hypoglycemia in patients with type 1 diabetes (T1D) and reduced the proportion of patients with hypoglycemia (blood glucose [BG] levels <54 mg/dL). There were no data on use of real-time CGM with algorithm-driven insulin pumps vs multiple daily injections with BG testing in people with T1D. CGM in outpatients with type 2 diabetes taking insulin and/or sulfonylureas reduced time spent with BG levels under 70 mg/dL. Initiation of CGM in hospitalized patients at high risk for hypoglycemia reduced episodes of hypoglycemia with BG levels lower than 54 mg/dL and time spent under 54 mg/dL. The proportion of patients with hypoglycemia with BG levels lower than 70 mg/dL and lower than 54 mg/dL detected by CGM was significantly higher than point-of-care BG testing. We found no data evaluating continuation of personal CGM in the hospital. Use of an inpatient computerized glycemic management program utilizing electronic health record data was associated with fewer patients with and episodes of hypoglycemia with BG levels lower than 70 mg/dL and fewer patients with severe hypoglycemia compared with standard care. Long-acting basal insulin analogs were associated with less hypoglycemia. Rapid-acting insulin analogs were associated with reduced severe hypoglycemia, though there were more patients with mild to moderate hypoglycemia. Structured diabetes education programs reduced episodes of severe hypoglycemia and time below 54 mg/dL in outpatients taking insulin. Glucagon formulations not requiring reconstitution were associated with longer times to recovery from hypoglycemia, although the proportion of patients who recovered completely from hypoglycemia was not different between the 2 groups.
Conclusion
This systematic review summarized the best available evidence about several interventions addressing hypoglycemia in people with diabetes. This evidence base will facilitate development of clinical practice guidelines by the Endocrine Society.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mayo Clinic Evidence-Based Practice Center, Rochester, MN 55902, USA.
- Olmsted Medical Center, Rochester, MN 55904, USA.
- Knowledge and Evaluation Research Unit, Department of Medicine, Mayo Clinic, Rochester, MN 55902, USA.
- College of Arts and Science, University of San Francisco, San Francisco, CA 94117, USA.
- Department of Library Services, Mayo Clinic, Rochester, MN 55902, USA.
- Division of Endocrine and Metabolic Disorders, Department of Internal Medicine, Eastern Virginia Medical School, Norfolk, VA 23501-1980, USA.
ORCID-Profile: Meritxell Urtecho, Tarek Nayfeh
Zitieren
APA
Torres Roldan, V. D., Urtecho, M., Nayfeh, T., Firwana, M., Muthusamy, K., Hasan, B., Abd-Rabu, R., Maraboto, A., Qoubaitary, A., Prokop, L., Lieb, D. C., McCall, A. L., Wang, Z., & Murad, M. H. (2023). A Systematic Review Supporting the Endocrine Society Guidelines: Management of Diabetes and High Risk of Hypoglycemia. The Journal of Clinical Endocrinology & Metabolism, 108(3), 592-603. https://doi.org/10.1210/clinem/dgac601
Vancouver
Torres Roldan VD, Urtecho M, Nayfeh T, Firwana M, Muthusamy K, Hasan B, et al. A Systematic Review Supporting the Endocrine Society Guidelines: Management of Diabetes and High Risk of Hypoglycemia. The Journal of Clinical Endocrinology & Metabolism. 2023;108(3):592-603. doi:10.1210/clinem/dgac601
BibTeX
@article{TorresRoldan2023,
author = {Torres Roldan, Victor D and Urtecho, Meritxell and Nayfeh, Tarek and Firwana, Mohammed and Muthusamy, Kalpana and Hasan, Bashar and Abd-Rabu, Rami and Maraboto, Andrea and Qoubaitary, Amjad and Prokop, Larry and Lieb, David C and McCall, Anthony L and Wang, Zhen and Murad, Mohammad Hassan},
title = {A Systematic Review Supporting the Endocrine Society Guidelines: Management of Diabetes and High Risk of Hypoglycemia},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
volume = {108},
number = {3},
pages = {592--603},
doi = {10.1210/clinem/dgac601}
}
EUVIMED